• en
  • it
  • de
  • Breaking News: PharmaZell Group acquired by Bridgepoint

    The PharmaZell Group management is very pleased to inform that the Group was acquired by Bridgepoint from DPE Deutsche Private Equity and Maxburg Capital Partners for an undisclosed sum. Bridgepoint is an international asset management firm with over €20 billion of assets under management.  Commenting on the transaction, PharmaZell CEO Dr. Oliver Bolzern, said: “We welcome Bridgepoint as our new shareholder. In Bridgepoint we have found a partner who understands our business and who will work with us to help us realize our ambitions for further growth.”. Carsten Kratz, Senior Partner of Bridgepoint, Frankfurt commented: “PharmaZell represents an exciting opportunity to invest in a robust platform with an experienced management team and a high-quality customer base in the growing and non-cyclical pharma market. With a strong track record of growth, the company also offers the prospect of further new products and with Bridgepoint will have the resources and reach to further develop selective acquisition opportunities.“. Guido Prehn, Managing Partner at DPE Deutsche Private Equity, added: “Since our investment into PharmaZell in early 2014, the company has generated double-digit annual growth almost doubling in size. It has been a fantastic partnership with management and we are truly happy to have found in Bridgepoint a new growth-focused home for this great company.” https://pharmazell-group.com/wp-content/uploads/2020/02/Bridgepoint-Press-Release.pdf

    Bridgepoint-Press-Release

    More News and Fairs

    Breaking News: PharmaZell Group acquired by Bridgepoint

    The PharmaZell Group management is very pleased to inform that the Group was acquired by Bridgepoint from DPE Deutsche Private Equity and Maxburg Capital Partners for an undisclosed sum. Bridgepoint

    UPDATE 4: IMPACT OF THE CURRENT COVID-19 OUTBREAK ON INDIAN PRODUCTION SITES

    PharmaZell Group is very conscious of our important role and duty in delivering APIs to our customers and being an active part in maintaining the health system running. Up to

    FarmaBios activities are regularly proceeding…

    During this critical and challenging period, Farmabios SpA states that our activities are regularly proceeding. We are conscious of the role and duty in delivering APIs, and our active part

    Farmabios Breaks Ground to Expand its Manufacturing Footprint in Gropello Cairoli (Italy)

    As part of an ongoing investment program to enhance PharmaZell Group’s production output, we have initiated the construction of a brand new large steroid building and a new warehouse on

    Renewed GMP Certificate for our Manufacturing Facility Farmabios in Gropello Cairoli (Italy)

    We are very glad to announce that the competent Italian authority (AIFA) has issued a renewed GMP certificate for our Farmabios SpA production facility [http://eudragmdp.ema.europa.eu/inspections/gmpc/generateGMPCPDF.do].

    Farmabios expands its portfolio with Cannabidiol API

    Global API supplier Farmabios announced today the addition of an ultra-pure synthetic Cannabidiol (CBD) drug substance to its portfolio. With an EU Drug Master File and cGMP manufacturing capacities, Farmabios